메뉴 건너뛰기
Multiple Sclerosis Journal
Volumn 19, Issue 7, 2013, Pages 861-862
Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: Commentary
Author keywords

[No Author keywords available]
Indexed keywords

CHRONIC CEREBROSPINAL VENOUS INSUFFICIENCY; CLINICAL RESEARCH; ENERGY; FUNDING; HUMAN; HYPERBARIC OXYGEN; IMMUNOPATHOGENESIS; INTELLECT; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC);
EID: 84878352639     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513490817     Document Type: Note
Times cited : (3)
References (7)
  • 1
    • 84920242058 scopus 로고
    • Hyperbaric oxygen and multiple sclerosis: Short-term results of a placebo-controlled, double-blind trial
    • Barnes MP, Bates D, Cartlidge NE, French JM, Shaw DA. Hyperbaric oxygen and multiple sclerosis: short-term results of a placebo-controlled, double-blind trial. Lancet. 1985 ; 1 (8424). 297-300
    • (1985) Lancet , vol.1 , Issue.8424 , pp. 297-300
    • Barnes, M.P.1    Bates, D.2    Cartlidge, N.E.3    French, J.M.4    Shaw, D.A.5
  • 2
    • 0023206028 scopus 로고
    • Hyperbaric oxygen and multiple sclerosis: Final results of a placebo-controlled, double-blind trial
    • Barnes MP, Bates D, Cartlidge NE, French JM, Shaw DA. Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial. J Neurol Neurosurg Psychiatry. 1987 ; 50: 1402-1406
    • (1987) J Neurol Neurosurg Psychiatry , vol.50 , pp. 1402-1406
    • Barnes, M.P.1    Bates, D.2    Cartlidge, N.E.3    French, J.M.4    Shaw, D.A.5
  • 3
    • 80051684615 scopus 로고    scopus 로고
    • Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
    • Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
    • (2011) Nature , vol.476 , pp. 214-219
    • Sawcer, S.1
  • 4
    • 84860780657 scopus 로고    scopus 로고
    • Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial
    • Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012 ; 78: 1069-1078
    • (2012) Neurology , vol.78 , pp. 1069-1078
    • Coles, A.J.1    Fox, E.2    Vladic, A.3
  • 5
    • 33644584352 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    • Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
    • (2006) N Engl J Med , vol.354 , pp. 899-910
    • Polman, C.H.1    O'Connor, P.W.2    Havrdova, E.3
  • 6
    • 76149140914 scopus 로고    scopus 로고
    • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    • Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
    • (2010) N Engl J Med , vol.362 , pp. 402-415
    • Cohen, J.A.1    Barkhof, F.2    Comi, G.3
  • 7
    • 84874136704 scopus 로고    scopus 로고
    • Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients
    • van Zuuren EJ, Fedorowicz Z, Pucci E, Jagannath VA, Robak EW. Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. Cochrane Database Syst Rev. 2012 ; 12 :
    • (2012) Cochrane Database Syst Rev , vol.12
    • Van Zuuren, E.J.1    Fedorowicz, Z.2    Pucci, E.3    Jagannath, V.A.4    Robak, E.W.5

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.